Eli Lilly specifies guidance for this year's revenue

The USD 200m increase in the estimated revenue from products within Eli Lilly's core business, leads the US company to specify its guidance for the 2021 revenue. Now, the pharmaceutical company expects a revenue in the range of USD 26.8bn-27.4bn.
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix

On Tuesday, US pharmaceutical company Eli Lilly detailed its guidance for the company's revenue for 2021 in connection with the publication of the pharmaceutical company's Q2 report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading